A Randomized, Double-blind, Placebo-controlled, Two-cohort, Parallel Group Study to Evaluate the Efficacy of CAD106 and CNP520 in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease
Phase of Trial: Phase II/III
Latest Information Update: 03 Oct 2017
At a glance
- Drugs Amilomotide (Primary) ; CNP 520 (Primary)
- Indications Alzheimer's disease
- Focus Therapeutic Use
- Acronyms Generation S1
- Sponsors Amgen; Novartis
- 06 Sep 2017 Planned End Date changed from 27 Aug 2023 to 6 May 2024.
- 06 Sep 2017 Planned primary completion date changed from 27 Aug 2023 to 6 May 2024.
- 10 Jun 2017 Biomarkers information updated